Skip to main content

A Novel Preclinical Candidate for Reducing Alpha-synuclein Aggregation in Parkinson’s Disease

Study Rationale: The goal of this program is to develop a novel drug for Parkinson’s disease (PD) with a unique mechanism of action. We have a drug candidate that shows potential as an inhibitor of the aggregation of alpha-synuclein. This drug candidate blocks a molecule called heparan sulfate glycosaminoglycan, which has been associated with alpha-synuclein aggregates and is thought to contribute to their toxic buildup and spread. During this program we will confirm our observations in a larger study and characterize the drug candidate for further clinical development.

Hypothesis: We hypothesize that by blocking heparan sulfate glycosaminoglycan, our drug candidate will inhibit the aggregation and spreading of alpha-synuclein, thereby minimizing neurodegeneration in preclinical PD models.

Study Design: We will first confirm the therapeutic effect of our leading drug candidate in a preclinical animal model of PD. Next, we will synthesize the drug candidate in larger quantities and subject it to a series of preclinical tests to evaluate its drug-like properties, metabolic stability and toxic liabilities. We also plan to optimize the drug for oral delivery.

Impact on Diagnosis/Treatment of Parkinson’s disease: Following the successful completion of these studies, we will have identified a safe and well-tolerated drug candidate. This candidate will be well-positioned for advancement toward Phase 1 studies. If successful, this project could yield a unique, disease-modifying approach to treat PD.

Next Steps for Development: We intend to continue IND-enabling preclinical studies, including optimization of dosing and route of administration and development of a clinical plan. Completion of the activities in this project should position this drug candidate on the pathway to be successful in IND filing and moving into Phase I clinical trials.


  • Paul Gregor, PhD

    Lexington, KY United States

  • Patrik Brundin, MD, PhD

    Grand Rapids, MI United States

Discover More Grants

Within the Same Program

Within the Same Funding Year

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.